 HONG KONG, Jan. 15, 2023 PRNewswire Akeso, Inc. 9926. HK Akeso, a commercial-stage biopharmaceutical company focused on developing and commercializing first-in-class and best-in-class innovative medicines globally, announced that the anti PD-1 monoclonal antibody drug Anniko penpulimab, co-developed by the Company with Sino Biopharmaceutical Limited 1177.HK together with its subsidiaries Sino Biopharm, combined with chemotherapy ...... 